4.8 Article

Antimicrobial functionalized genetically engineered spider silk

期刊

BIOMATERIALS
卷 32, 期 18, 页码 4255-4266

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2011.02.040

关键词

Spider silk; Antimicrobial activity; Recombinant proteins; Self-assembly; Cell viability; Bone tissue engineering

资金

  1. Portuguese Foundation for Science and Technology (FCT) [SFRH/BD/28603/2006]
  2. EU-EC [NMP3-CT-2004-500283]
  3. FCT agency [PTDC/EBB-EBI/109093/2008]
  4. NIH Tissue Engineering Resource Center [P41 EB002520]
  5. NIH [EB003210, DE017207]
  6. Fundação para a Ciência e a Tecnologia [PTDC/FIS/68517/2006, PTDC/EBB-EBI/109093/2008, SFRH/BD/28603/2006] Funding Source: FCT

向作者/读者索取更多资源

Genetically engineered fusion proteins offer potential as multifunctional biomaterials for medical use. Fusion or chimeric proteins can be formed using recombinant DNA technology by combining nucleotide sequences encoding different peptides or proteins that are otherwise not found together in nature. In the present study, three new fusion proteins were designed, cloned and expressed and assessed for function, by combining the consensus sequence of dragline spider silk with three different antimicrobial peptides. The human antimicrobial peptides human neutrophil defensin 2 (HNP-2), human neutrophil defensins 4 (HNP-4) and hepcidin were fused to spider silk through bioengineering. The spider silk domain maintained its self-assembly features, a key aspect of these new polymeric protein biomaterials, allowing the formation of beta-sheets to lock in structures via physical interactions without the need for chemical cross-linking. These new functional silk proteins were assessed for antimicrobial activity against Gram - Escherichia coli and Gram + Staphylococcus aureus and microbicidal activity was demonstrated. Dynamic light scattering was used to assess protein aggregation to clarify the antimicrobial patterns observed. Attenuated-total reflectance Fourier transform infrared spectroscopy (ATR-FTIR) and circular dichroism (CD) were used to assess the secondary structure of the new recombinant proteins. In vitro cell studies with a human osteosarcoma cell line (SaOs-2) demonstrated the compatibility of these new proteins with mammalian cells. (C) 2011 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据